| Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold primarily to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics and government agencies. Co. manufactures products in the U.S. and Puerto Rico and has manufacturing operations in several foreign countries. Co. has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. We show 41 historical shares outstanding datapoints in our CELG shares outstanding history coverage, used to compute CELG market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CELG market cap history over the course of time is important for investors
interested in comparing CELG's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CELG versus a peer is one thing; comparing
CELG market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CELG can fluctuate over the course of history.
With this page we aim to empower investors researching CELG by allowing them to research the CELG market cap history.